Results 191 to 195 of about 1,521,289 (195)

Identification of biomarkers of shrinkage modes after neoadjuvant therapy in HER-2 positive breast cancer. [PDF]

Int J Surg
Bi Z, Zhang Y, Song XR, Zheng WH, Chen P, Qiu PF, Liu YB, Lu YJ, Song XG, Wang YS.   +9 more
europepmc   +1 more source

Development of Novel Neratinib and Docetaxel Core-Loaded and Trastuzumab Surface-Conjugated Nanoparticle for Treatment of HER-2 Positive Breast Cancer. [PDF]

Pharmaceutics
Ejigah V, Battogtokh G, Mandala B, Akala EO.   +3 more
europepmc   +1 more source

Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer. [PDF]

Medicina (Kaunas)
Günaltılı M, Guliyev M, Fidan MC, Birsin Z, Çerme E, Aliyev V, Abbasov H, Cebeci S, Jeral S, Alan Ö, Demirci NS, Papila Ç, Şahin OE, Bıyıkoğlu SE, Öztürk T, Papila B.   +15 more
europepmc   +1 more source

Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1<i>H</i>)-ones as dual EGFR/HER-2 inhibitors. [PDF]

Front Chem
Al-Wahaibi LH, Abou-Zied HA, Nieger M, Bräse S, Youssif BGM, Tawfeek HN.   +5 more
europepmc   +1 more source

Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy. [PDF]

Am J Cancer Res
Chen X, Ji L, Qian X, Xiao M, Li Q, Li Q, Wang J, Fan Y, Luo Y, Lan B, Chen S, Ma F, Xu B, Zhang P.   +13 more
europepmc   +1 more source